The Actinic (Solar) Keratosis drugs in development market research report provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Actinic (Solar) Keratosis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued products.

GlobalData tracks 24 drugs in development for Actinic (Solar) Keratosis by 25 companies/universities/institutes. The top development phase for Actinic (Solar) Keratosis is preclinical with ten drugs in that stage. The Actinic (Solar) Keratosis pipeline has 24 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Actinic (Solar) Keratosis pipeline products market are: Maruho, Coegin Pharma and MediWound.

The key targets in the Actinic (Solar) Keratosis pipeline products market include Tubulin , Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS), and Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A).

The key mechanisms of action in the Actinic (Solar) Keratosis pipeline product include Tubulin Inhibitor with two drugs in Pre-Registration. The Actinic (Solar) Keratosis pipeline products include 12 routes of administration with the top ROA being Topical and four key molecule types in the Actinic (Solar) Keratosis pipeline products market including Small Molecule, and Enzyme.

Actinic (Solar) Keratosis overview

An actinic keratosis, also known as a solar keratosis, is a scaly or crusty growth (lesion). It most often appears on the bald scalp, face, ears, lips, backs of the hands and forearms, shoulders, neck, or any other areas of the body frequently exposed to the sun. The signs and symptoms of an actinic keratosis include a hard, wart-like surface, patch or bump on the top layer of skin, itching or burning in the affected area, and color as varied as pink, red or brown, or flesh-colored. The predisposing factors include age, sunny climate, history of frequent or intense sun exposure or sunburn, pale skin, red or blond hair, blue or light-colored eyes, and a weak immune system as a result of chemotherapy, chronic leukemia, AIDS, or organ transplant medications.

For a complete picture of Actinic (Solar) Keratosis’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.